A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a study that will look at the effects and how useful investigational drug olaparib is
as a neoadjuvant treatment (treatment given as to shrink a tumor before the main treatment)
prior to surgery in patients with recurrent ovarian, primary peritoneal or fallopian tube
cancer.